Senthil Sundaram's most recent trade in Terns Pharmaceuticals Inc was a trade of 900,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 1, 2023.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Terns Pharmaceuticals Inc | Senthil Sundaram | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 900,000 | 900,000 | - | - | Stock Option (Right to Buy) | |
Terns Pharmaceuticals Inc | Senthil Sundaram | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.33 per share. | 01 Feb 2023 | 3 | 7,659 | - | 1.3 | 4 | Common Stock |
Terns Pharmaceuticals Inc | Senthil Sundaram | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.47 per share. | 31 May 2022 | 7,656 | 7,656 | - | 1.5 | 11,254 | Common Stock |
Terns Pharmaceuticals Inc | Senthil Sundaram | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Sep 2021 | 315,000 | 315,000 | - | - | Stock Option (Right to Buy) |